The estimated Net Worth of Jeffrey Ryan Stewart is at least $37.5 Milión dollars as of 18 March 2024. Mr. Stewart owns over 58,949 units of Abbvie Inc stock worth over $11,858,509 and over the last 6 years he sold ABBV stock worth over $25,658,189. In addition, he makes $0 as Senior Vice President a U.S. Commercial Operations at Abbvie Inc.
Jeffrey has made over 9 trades of the Abbvie Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 58,949 units of ABBV stock worth $10,539,492 on 18 March 2024.
The largest trade he's ever made was selling 58,949 units of Abbvie Inc stock on 18 March 2024 worth over $10,539,492. On average, Jeffrey trades about 10,480 units every 73 days since 2018. As of 18 March 2024 he still owns at least 60,941 units of Abbvie Inc stock.
You can see the complete history of Mr. Stewart stock trades at the bottom of the page.
Jeffrey R. Stewart is the Senior Vice President, U.S. Commercial Operations of the Company. Mr. Stewart previously served as AbbVie’s President, Commercial Operations from 2013 to 2018. Prior to AbbVie’s separation from Abbott, he served as Vice President, Abbott Proprietary Pharmaceutical Division, United States. Mr. Stewart joined Abbott in 1992.
Jeffrey Stewart is 50, he's been the Senior Vice President a U.S. Commercial Operations of Abbvie Inc since 2018. There are 28 older and 4 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is North Waukegan Road, North Chicago, Lake County, Illinois, 60044, United States.
Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell a Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Abbvie Inc executives and other stock owners filed with the SEC include: